StocksMediumUpdated•Originally published 3 November 2026•Updated 3 November 2026•
1 min read
Teva Pharmaceutical Beats Q3 2026 Profit Estimates
Key Facts
1Teva Pharmaceutical reported Q3 profits that exceeded analyst estimates.
Teva Pharmaceutical's earnings per share exceeded estimates by $0.14 during the third quarter of 2026. Reuters reported that the company's revenue also surpassed market expectations during this financial period.
Teva Pharmaceutical shares closed at $40.7 on November 2, 2026. During that session, the stock reached a high of $42 and a low of $40.63.